SpectraScience, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Firm nets approximately $4.2 mil. through a series of transactions, including a $3.5 mil. private placement, $396,804 in stock option exercises and $600,000 from an equity securities transaction. The funds improve the firm's financial position following a recent move to an expanded manufacturing facility and positive FDA panel review of its Virtual Biopsy system. The agency's Gastroenterology and Urology Devices Panel voted 4-3 to recommend approval of the laser-induced fluorescence technology on Nov. 19 (1"The Gray Sheet" Nov. 29, p. 3)